Apixaban Therapy Duration and Peri‑operative Management Guidelines

Non‑Valvular Atrial Fibrillation (NVAF)

Dose‑reduction criteria – Use the reduced dose of 2.5 mg twice daily when a patient meets ≥ 2 of the following: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL. (Society of Anesthesiologists) [1][2]
Ongoing therapy – Continue apixaban indefinitely for stroke prevention, with annual reassessment of the risk‑benefit balance; discontinuation is rarely appropriate unless bleeding risk becomes prohibitive. (American College of Cardiology) [3][4]

Initial dosing – Begin treatment with 10 mg orally twice daily for the first 7 days, then reduce to 5 mg twice daily for the remainder of therapy. (American College of Cardiology) 4
Minimum treatment duration –
- Provoked VTE (e.g., surgery, trauma, immobility): treat for ≥ 3 months. (American College of Cardiology) [3][4]
- Unprovoked or persistent‑risk VTE: treat for ≥ 6 months. (American College of Cardiology; Blood Advances) [3][5]
Extended therapy – After completing the initial 6‑month course, patients with unprovoked VTE may continue apixaban indefinitely, either at the standard dose (5 mg BID) or reduced dose (2.5 mg BID). (Blood Advances) 5
Dose choice for extended therapy – Standard‑dose and reduced‑dose regimens show comparable efficacy for preventing recurrent VTE and similar bleeding rates. (Blood Advances) 5

Hip replacement – Administer apixaban 2.5 mg twice daily for 32–38 days (≈ 5 weeks), starting 12–24 h after wound closure. (Society of Anesthesiologists) [1][6]7
Knee replacement – Administer apixaban 2.5 mg twice daily for 10–14 days (≈ 2 weeks), starting 12–24 h after wound closure. (Society of Anesthesiologists) [1][6]7
Timing of first dose – Do not give apixaban pre‑operatively; the first dose should be given 12–24 h post‑surgery to minimize bleeding risk. (American College of Chest Physicians) 6

Low‑to‑moderate bleeding‑risk procedures – Stop apixaban 1 day before the procedure (skip 2 doses). (Canadian Cardiovascular Society; Blood; American College of Chest Physicians) [8][9]10
High‑bleeding‑risk procedures – Stop apixaban 2 days before the procedure (skip 4 doses). (Canadian Cardiovascular Society; Blood; Society of Anesthesiologists; American College of Chest Physicians) [8][9][1][10]
Neuraxial anesthesia – Discontinue apixaban ≥ 2–3 days (48–72 h) before spinal or epidural anesthesia to avoid epidural hematoma. (Canadian Cardiovascular Society; Society of Anesthesiologists; American College of Chest Physicians) [8][1]10
Minimal‑bleeding‑risk procedures (e.g., dental extraction, cataract surgery, pacemaker implantation, minor dermatologic procedures) – Continue apixaban without interruption. (American College of Chest Physicians) 10

Low‑bleeding‑risk surgery – Resume apixaban 24 h post‑operatively at the full therapeutic dose (5 mg BID for VTE/AF; 2.5 mg BID for orthopedic prophylaxis). (Canadian Cardiovascular Society; Blood; Society of Anesthesiologists) [8][9]2
High‑bleeding‑risk surgery – Resume apixaban 48–72 h post‑operatively once hemostasis is confirmed, at the full therapeutic dose. (Canadian Cardiovascular Society; Blood; Society of Anesthesiologists) [8][9][1][2]
Bridging therapy – Not recommended when interrupting apixaban for surgery because of its rapid offset (half‑life 8–14 h) and rapid onset. (Society of Anesthesiologists; American College of Chest Physicians) [1][10]
Exception – Bridging may be considered only in patients at very high thrombotic risk (e.g., mechanical heart valve, stroke/TIA ≤ 3 months, CHADS₂ ≥ 5); however, apixaban is contraindicated in mechanical valve patients. (Canadian Cardiovascular Society; Society of Anesthesiologists) [8][1]

Renal function – Apixaban is ~27 % renally eliminated. Avoid in severe renal impairment (CrCl < 15 mL/min). Use reduced dosing when CrCl 15–29 mL/min and other dose‑reduction criteria are present. (Journal of the National Comprehensive Cancer Network; Society of Anesthesiologists) [12][2]
Drug interactions – Avoid concomitant use of strong dual inhibitors of CYP3A4 and P‑glycoprotein (e.g., ketoconazole, ritonavir) because they markedly increase apixaban plasma levels. (American College of Chest Physicians; Society of Anesthesiologists) [13][6]7
Early‑phase acute VTE surgery – If surgery is required during the first 3 weeks of DVT/PE treatment (when higher apixaban doses are used), a multidisciplinary discussion is required as standard peri‑operative protocols may not apply. (Society of Anesthesiologists) 1